Bank of the West’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $8.9M | Buy |
55,067
+905
| +2% | +$139K | 1.05% | 23 |
|
|
2022
Q3 | $7.27M | Sell |
54,162
-1,137
| -2% | -$163K | 0.95% | 25 |
|
|
2022
Q2 | $8.47M | Sell |
55,299
-1,072
| -2% | -$164K | 1.07% | 23 |
|
|
2022
Q1 | $9.14M | Sell |
56,371
-571
| -1% | -$82.9K | 0.94% | 28 |
|
|
2021
Q4 | $7.71M | Buy |
56,942
+2,604
| +5% | +$308K | 0.73% | 40 |
|
|
2021
Q3 | $5.86M | Buy |
54,338
+784
| +1% | +$89.6K | 0.61% | 49 |
|
|
2021
Q2 | $6.03M | Sell |
53,554
-2,128
| -4% | -$240K | 0.61% | 50 |
|
|
2021
Q1 | $6.03M | Buy |
55,682
+1,674
| +3% | +$179K | 0.68% | 47 |
|
|
2020
Q4 | $5.79M | Buy |
54,008
+4,216
| +8% | +$405K | 0.68% | 45 |
|
|
2020
Q3 | $4.36M | Sell |
49,792
-800
| -2% | -$75.3K | 0.59% | 46 |
|
|
2020
Q2 | $4.97M | Buy |
50,592
+780
| +2% | +$68.7K | 0.67% | 38 |
|
|
2020
Q1 | $3.79M | Sell |
49,812
-7,500
| -13% | -$639K | 0.59% | 46 |
|
|
2019
Q4 | $5.07M | Sell |
57,312
-1,588
| -3% | -$132K | 0.59% | 50 |
|
|
2019
Q3 | $4.46M | Buy |
58,900
+5,426
| +10% | +$372K | 0.54% | 50 |
|
|
2019
Q2 | $3.89M | Sell |
53,474
-3,429
| -6% | -$270K | 0.46% | 64 |
|
|
2019
Q1 | $4.59M | Sell |
56,903
-54
| -0.1% | -$4.42K | 0.54% | 50 |
|
|
2018
Q4 | $5.25M | Buy |
56,957
+1,769
| +3% | +$156K | 0.63% | 41 |
|
|
2018
Q3 | $5.22M | Sell |
55,188
-541
| -1% | -$51.3K | 0.61% | 47 |
|
|
2018
Q2 | $5.16M | Sell |
55,729
-1,528
| -3% | -$149K | 0.63% | 45 |
|
|
2018
Q1 | $5.42M | Sell |
57,257
-1,403
| -2% | -$154K | 0.68% | 41 |
|
|
2017
Q4 | $5.67M | Sell |
58,660
-4,342
| -7% | -$409K | 0.71% | 42 |
|
|
2017
Q3 | $5.6M | Sell |
63,002
-55,920
| -47% | -$4.26M | 0.71% | 47 |
|
|
2017
Q2 | $8.62M | Sell |
118,922
-933
| -0.8% | -$62.7K | 1.11% | 19 |
|
|
2017
Q1 | $7.81M | Sell |
119,855
-606
| -0.5% | -$38.1K | 0.98% | 22 |
|
|
2016
Q4 | $7.54M | Buy |
120,461
+2,399
| +2% | +$146K | 1.04% | 20 |
|
|
2016
Q3 | $7.45M | Sell |
118,062
-6,691
| -5% | -$433K | 1.03% | 25 |
|
|
2016
Q2 | $7.72M | Buy |
124,753
+10,817
| +9% | +$659K | 1.1% | 23 |
|
|
2016
Q1 | $6.51M | Buy |
113,936
+3,221
| +3% | +$180K | 0.9% | 31 |
|
|
2015
Q4 | $6.56M | Buy |
110,715
+5,308
| +5% | +$306K | 0.91% | 31 |
|
|
2015
Q3 | $5.74M | Sell |
105,407
-7,603
| -7% | -$495K | 0.91% | 29 |
|
|
2015
Q2 | $7.59M | Buy |
113,010
+235
| +0.2% | +$15.3K | 1.08% | 23 |
|
|
2015
Q1 | $6.6M | Sell |
112,775
-1,636
| -1% | -$98.8K | 0.93% | 29 |
|
|
2014
Q4 | $7.49M | Buy |
114,411
+4,457
| +4% | +$281K | 1.09% | 21 |
|
|
2014
Q3 | $6.35M | Sell |
109,954
-4,607
| -4% | -$256K | 1.08% | 24 |
|
|
2014
Q2 | $6.46M | Sell |
114,561
-4,209
| -4% | -$221K | 1.01% | 26 |
|
|
2014
Q1 | $6.11M | Buy |
118,770
+8,154
| +7% | +$412K | 1% | 26 |
|
|
2013
Q4 | $5.84M | Buy |
110,616
+363
| +0.3% | +$17.8K | 0.93% | 29 |
|
|
2013
Q3 | $4.93M | Buy |
110,253
+4,824
| +5% | +$214K | 0.9% | 33 |
|
|
2013
Q2 | $4.36M | Buy |
+105,429
| New | +$4.61M | 0.82% | 40 |
|
Other funds holding ABBV
AWA
Bank of the West's ABBV Position: Q4 2022 in Review
Bank of the West increased its AbbVie (ABBV) stake by 1.7% in Q4 2022, buying an estimated $139K and bringing the position to 55,067 shares worth $8.9M. The position accounts for 1.05% of the portfolio, ranked #23.
Bank of the West first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $9.14M in Q1 2022. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.
- Bank of the West held 55,067 shares of AbbVie worth $8.9M as of Q4 2022.
- Bank of the West bought 905 AbbVie shares in Q4 2022, an estimated $139K.
- AbbVie made up 1.05% of Bank of the West's portfolio in Q4 2022, its #23 holding.
- Bank of the West first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
- Bank of the West's AbbVie position peaked at $9.14M in Q1 2022.
- 3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.
Based on Bank of the West's 13F filing for Q4 2022, filed 1 Feb 2023.